{"product_id":"zvra-business-model-canvas","title":"(ZVRA) Zevra Therapeutics, Inc. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra Therapeutics: Rare-Disease Business Model in One Glance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Zevra Therapeutics, Inc.'s business model. This concise Business Model Canvas highlights how the company creates value, builds partnerships, and advances rare-disease therapies in a competitive biotech market. Ideal for investors, analysts, and strategists who want actionable insight fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKVK-Tech, Inc. licensing agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has a collaboration and licensing agreement with KVK-Tech, Inc. that supports commercialization, product development, and supply-chain execution for its LAT-based portfolio. The deal also helps extend the reach of approved and in-market therapies, backing Zevra Therapeutics, Inc.'s path to broader patient access and future pipeline work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommave Therapeutics SA licensing agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra’s licensing deal with Commave Therapeutics SA gives it rights to arimoclomol, the basis for MIPLYFFA, its 1 approved rare-disease asset after the FDA’s 2024 approval for Niemann-Pick disease type C. This access to externally developed IP helps cut time to market and keeps Zevra’s pipeline broader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA regulatory counterpart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. depends on the FDA as its key regulatory counterpart: 2 approved products, AZSTARYS and APADAZ, plus the KP1077 and KP879 pipeline, all need approval, safety review, and trial oversight. This is a core external link, not a commercial partner, because regulatory alignment can decide speed to market and label scope.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical research organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical research organizations are core to Zevra Therapeutics, Inc.’s Phase II execution, especially across idiopathic hypersomnia, narcolepsy, and stimulant use disorder. They add operational scale, site management, and data handling, helping Zevra move 3 active mid-stage programs faster and with lower fixed overhead than building a full in-house trial team.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupport 3 Phase II programs\u003c\/li\u003e\n\u003cli\u003eRun sites and patient flow\u003c\/li\u003e\n\u003cli\u003eHandle trial data and compliance\u003c\/li\u003e\n\u003cli\u003eReduce internal operating burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eContract manufacturing and supply partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. relies on contract manufacturers and packagers to make and ship approved products and clinical candidates, since biopharma production needs specialized equipment, GMP controls, and controlled-substance handling. In FY2025, this support was critical to keep supply steady for rare-disease therapies and late-stage programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtects quality and compliance\u003c\/li\u003e\n\u003cli\u003eKeeps supply continuity stable\u003c\/li\u003e\n\u003cli\u003eSupports specialty drug packaging\u003c\/li\u003e\n\u003cli\u003eReduces manufacturing bottlenecks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Partner Network Powers Rare-Disease Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. leans on KVK-Tech, Inc., Commave Therapeutics SA, the FDA, CROs, and GMP manufacturers to move rare-disease assets from approval to supply. These links support MIPLYFFA, AZSTARYS, APADAZ, and the Phase II pipeline while lowering fixed cost and execution risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKVK-Tech, Inc.\u003c\/td\u003e\n\u003ctd\u003eCommercial and supply\u003c\/td\u003e\n\u003ctd\u003eLAT portfolio execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommave Therapeutics SA\u003c\/td\u003e\n\u003ctd\u003eIP license\u003c\/td\u003e\n\u003ctd\u003eMIPLYFFA rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e2 approved products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Business Model Canvas for Zevra Therapeutics, mapping its rare-disease drug development, partnerships, and commercialization strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Zevra Therapeutics’ key business model pain points with a clear, one-page snapshot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Zevra Therapeutics, Inc. to verify claims fast and support confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelop LAT-based prodrugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics centers its Ligand Activated Therapy (LAT) platform on designing prodrugs from FDA-approved molecules to improve dosing, utility, and new uses. The model is already commercial, with MIPLYFFA approved in 2024 for Niemann-Pick disease type C, showing the platform can move one LAT asset from design to market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRun Phase II clinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. runs Phase II studies for KP1077 in idiopathic hypersomnia and narcolepsy, plus KP879 in stimulant use disorder. These trials generate the efficacy and safety data needed to decide Phase III entry, and they are central to pipeline value creation because they de-risk two clinical assets at once.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialize approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra commercializes AZSTARYS for ADHD in patients 6 years and older and APADAZ, an immediate-release hydrocodone\/acetaminophen product. Revenue depends on physician adoption, payer access, and steady supply, so this activity provides the company’s current sales base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManage regulatory and quality systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. must keep FDA filings, labeling, pharmacovigilance, and CMC (chemistry, manufacturing, and controls) tight across its 2 approved U.S. therapies, MIPLYFFA and OLPRUVA. For controlled-substance and rare-disease products, strong quality systems cut launch delays, recall risk, and post-market compliance issues.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA submissions stay on schedule\u003c\/li\u003e\n\u003cli\u003eLabeling matches approved use\u003c\/li\u003e\n\u003cli\u003eSafety signals are tracked fast\u003c\/li\u003e\n\u003cli\u003eCMC controls protect product quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvance rare-disease portfolio strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. advances a rare-disease portfolio by focusing on high-unmet-need CNS and orphan targets, then picking indications with clear differentiation and commercial upside. With 2 approved rare-disease therapies, MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders, Zevra uses sequencing and capital allocation to shape long-term growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets high-unmet-need CNS\/rare diseases\u003c\/li\u003e\n\u003cli\u003ePicks differentiated, commercial assets\u003c\/li\u003e\n\u003cli\u003eSequences programs and allocates capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Rare-Disease Portfolio Grows With 2 Approvals and 2 Phase II Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. Key Activities center on LAT prodrug design, late-stage clinical development, and commercial execution for MIPLYFFA, OLPRUVA, AZSTARYS, and APADAZ. In 2025, it had 2 approved rare-disease therapies and 2 commercial products, while Phase II work in KP1077 and KP879 kept pipeline value moving.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved therapies\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial products\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Phase II assets\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis Zevra Therapeutics, Inc. Business Model Canvas preview is the exact document you will receive after purchase. It’s not a sample or placeholder—what you see here is a direct view of the final file. Once purchased, you’ll get the same professionally formatted document in full, ready to use, edit, or share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLigand Activated Therapy platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics' Ligand Activated Therapy platform is its core proprietary asset, and it underpins 2 FDA-approved medicines. LAT lets Zevra turn known compounds into new prodrug formulations, supporting both marketed products and pipeline candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved products AZSTARYS and APADAZ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has two FDA-approved products, AZSTARYS for ADHD and APADAZ for immediate-release pain, giving the company commercial proof of concept and a real operating base. These marketed assets support ongoing revenue generation while Zevra keeps building its pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II pipeline assets KP1077 and KP879\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKP1077 and KP879 are Zevra Therapeutics, Inc. Phase II pipeline assets and key near-term growth drivers. KP1077 targets idiopathic hypersomnia and narcolepsy, while KP879 targets stimulant use disorder, giving Zevra Therapeutics, Inc. a path into two large, underpenetrated markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntellectual property and licensing rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. relies on patents and license deals to protect exclusivity on approved and pipeline assets, which is key in specialty pharma where one lost year can mean a fast drop in pricing power. In 2025, Zevra reported $15.0 million in Q1 revenue and held $123.4 million in cash and equivalents, so protecting licensed rights is central to future value capture.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent walls defend exclusivity\u003c\/li\u003e\n\u003cli\u003eLicenses add external assets\u003c\/li\u003e\n\u003cli\u003eSupports higher-margin pricing\u003c\/li\u003e\n\u003cli\u003eCritical for specialty pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific, clinical, and regulatory expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. relies on small, specialized teams to move rare-disease assets from clinic to market. With 2 FDA-approved therapies in 2025, scientific, clinical, regulatory, and CMC experts are essential for trial design, filings, manufacturing control, and launch execution; commercial and medical staff then help convert approval into uptake.\u003c\/p\u003e\n\u003cp\u003eHuman capital is the key execution resource because rare-disease programs need cross-functional speed and precision, not broad headcount.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical teams shape trial design\u003c\/li\u003e\n\u003cli\u003eRegulatory teams manage filings\u003c\/li\u003e\n\u003cli\u003eCMC teams protect product quality\u003c\/li\u003e\n\u003cli\u003eCommercial teams support launch\u003c\/li\u003e\n\u003cli\u003eMedical teams support adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s approved products and cash fuel its pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc.'s key resources are its Ligand Activated Therapy platform, FDA-approved products AZSTARYS and APADAZ, and patent- and license-backed exclusivity. These assets, plus specialized regulatory, clinical, CMC, and commercial talent, support both current revenue and pipeline execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-approved products\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 revenue\u003c\/td\u003e\n\u003ctd\u003e$15.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and equivalents\u003c\/td\u003e\n\u003ctd\u003e$123.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovel prodrug innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics turns FDA-approved molecules into new therapy options through its LAT prodrug approach, aiming to improve how medicines are used in clinic without starting from a new chemical entity. This lowers discovery risk and can speed differentiation versus de novo drugs while creating value from known assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare-disease focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. focuses on severe rare diseases with few options, such as Niemann-Pick disease type C, a condition seen in about 1 in 100,000 births. That scarcity of treatment choice can support premium pricing, strong clinical differentiation, and high-value niche demand.\u003c\/p\u003e\n\u003cp\u003eIts 2025 portfolio includes FDA-approved MIPLYFFA, the first treatment for NPC, which makes the rare-disease focus commercially meaningful as well as medically urgent.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved ADHD treatment for age 6+\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAZSTARYS gives Zevra Therapeutics, Inc. a marketed ADHD therapy approved for patients age 6+, with once-daily dosing that fits pediatric and older use. It is a real commercial asset in a large behavioral health market, and having an approved product helps validate Zevra Therapeutics, Inc.’s platform and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline in sleep and stimulant-use disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKP1077 targets idiopathic hypersomnia and narcolepsy, while KP879 targets stimulant use disorder, giving Zevra Therapeutics, Inc. exposure to two CNS areas with few effective options and high unmet need. This pipeline can broaden Zevra Therapeutics, Inc. beyond approved products and capture larger sleep and addiction markets as clinical data mature.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKP1077: sleep disorders\u003c\/li\u003e\n\u003cli\u003eKP879: stimulant use disorder\u003c\/li\u003e\n\u003cli\u003eExpands beyond approved products\u003c\/li\u003e\n\u003cli\u003eTargets major CNS unmet needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty pharma with controlled-substance expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. brings niche know-how in tightly regulated markets where ADHD, pain, and stimulant-related drugs often sit under DEA Schedule II-V controls. That matters because harder access rules, prior auth, and abuse-risk checks can slow launches; strong execution helps build doctor and payer trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFits complex, regulated therapies\u003c\/li\u003e\n\u003cli\u003eSupports access and reimbursement\u003c\/li\u003e\n\u003cli\u003eBuilds confidence with physicians\u003c\/li\u003e\n\u003cli\u003eHelps manage abuse-risk scrutiny\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Rare-Disease Play: First NPC Drug, Once-Daily ADHD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. creates value by repurposing known molecules for severe rare diseases, led by MIPLYFFA, the first FDA-approved treatment for NPC, and AZSTARYS, a once-daily ADHD therapy for ages 6+.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eValue hook\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIPLYFFA\u003c\/td\u003e\n\u003ctd\u003eFirst NPC treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAZSTARYS\u003c\/td\u003e\n\u003ctd\u003eOnce-daily ADHD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physician engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. relies on a small base of CNS, sleep, and pain specialists, so adoption depends on medical-affairs-led education, dosing support, and clear clinical data. For rare-disease launches like MIPLYFFA for Niemann-Pick disease type C, these physician ties help explain appropriate use and product value in a market with limited prescriber volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient access support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient access support helps Zevra Therapeutics, Inc. clear prior authorization and reimbursement hurdles that can delay specialty drug starts. For rare and controlled-substance therapies, this support improves treatment initiation and persistence by reducing payer friction and helping patients stay on therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and formulary coordination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayer and formulary coordination is critical for Zevra Therapeutics, Inc. because pharmacy benefit managers manage coverage for roughly 270 million U.S. lives, and formulary placement can make or break prescription pull-through and refill persistence.\u003c\/p\u003e\n\u003cp\u003eFor rare-disease drugs, every coverage win matters: better access usually means higher script volume, faster revenue conversion, and fewer abandoned starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty pharmacy fulfillment support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. uses specialty pharmacy fulfillment support to manage controlled-channel ordering, dispensing, and patient onboarding for products like AZSTARYS and APADAZ. This setup helps tighten safety checks and compliance, while improving fill coordination for therapies that need close handling.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControls ordering and dispensing.\u003c\/li\u003e\n\u003cli\u003eSupports patient onboarding.\u003c\/li\u003e\n\u003cli\u003eImproves safety and compliance.\u003c\/li\u003e\n\u003cli\u003eFits AZSTARYS and APADAZ.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical information and post-market support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare stakeholders need clear product info and safety follow-up, so Zevra Therapeutics, Inc. must keep fast response channels for clinicians and patients. Strong post-market support helps build trust, improve adherence, and feeds pharmacovigilance and lifecycle management as products scale after launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast clinician and patient responses\u003c\/li\u003e\n\u003cli\u003eSafety follow-up and reporting\u003c\/li\u003e\n\u003cli\u003eAdherence support after launch\u003c\/li\u003e\n\u003cli\u003eFeeds pharmacovigilance and lifecycle work\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Rare-Disease Support Engine Can Drive Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. builds customer ties through rare-disease specialist education, access support, and payer coordination, which matter most for MIPLYFFA and other niche therapies. In 2025, this model is aimed at a small prescriber base and high-friction coverage paths, where each approved start can meaningfully lift revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCustomer relationship lever\u003c\/th\u003e\n\u003cth\u003e2025 relevance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist education\u003c\/td\u003e\n\u003ctd\u003eSmall CNS and rare-disease prescriber base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess support\u003c\/td\u003e\n\u003ctd\u003ePrior auth and reimbursement help\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coordination\u003c\/td\u003e\n\u003ctd\u003eCoverage can affect script pull-through\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacy networks are a key route for Zevra Therapeutics, Inc. because they handle complex dispensing, prior auth, refill tracking, and adherence support for targeted therapies. This channel is especially fit for ADHD and other controlled products, where access rules matter and patient services can lift starts and stays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers and distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAZSTARYS and APADAZ are FDA-approved medicines, so Zevra Therapeutics, Inc. uses wholesalers and distributors to place product into pharmacy networks, expand availability, and keep inventory moving. This is a standard pharma route to market and helps support supply continuity and lower stockout risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare provider sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics uses a focused healthcare provider sales force to reach prescribers in rare-disease settings, where launch adoption depends on direct education. Sales and medical teams explain product differentiation and appropriate use, turning clinical evidence into prescriptions; this matters in narrow markets like NPC, a disease affecting about 1 in 100,000 births.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital and medical education channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. uses digital outreach and medical education to reach specialty clinicians and rare-disease centers that field teams cannot cover often. These channels help explain product profile and trial data, and they support conference activity while staying efficient in small, high-value patient pools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReaches hard-to-find specialty niches\u003c\/li\u003e\n\u003cli\u003eExplains trial data clearly\u003c\/li\u003e\n\u003cli\u003eSupports field and conference work\u003c\/li\u003e\n\u003cli\u003eFits rare-disease awareness needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner licensing and distribution pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. uses partner licensing to extend reach beyond its own sales base, which fits an asset-light specialty model. In 2024, the Company booked $15.6 million in product revenue, while collaboration and licensing structures help scale assets without matching that growth with a full commercial build.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtends commercialization reach\u003c\/li\u003e\n\u003cli\u003eLowers operating burden\u003c\/li\u003e\n\u003cli\u003eFits asset-light specialty strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Rare-Disease Go-to-Market: Specialty Access That Works\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. reaches patients through specialty pharmacies, wholesalers, field sales, and partner licensing, with digital medical education supporting rare-disease prescribers. This fits narrow markets like NPC, which affects about 1 in 100,000 births, and helps handle access, prior auth, and refill control.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy\u003c\/td\u003e\n\u003ctd\u003eDispense and adherence support\u003c\/td\u003e\n\u003ctd\u003eBest for controlled, complex therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\/distributors\u003c\/td\u003e\n\u003ctd\u003ePlace approved products\u003c\/td\u003e\n\u003ctd\u003eSupports inventory continuity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField and digital\u003c\/td\u003e\n\u003ctd\u003eEducate rare-disease prescribers\u003c\/td\u003e\n\u003ctd\u003eNPC prevalence ~1 in 100,000 births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with ADHD aged 6+\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAZSTARYS targets patients with ADHD aged 6+, a large diagnosis-driven pool; the CDC says about 7.1 million U.S. children aged 3-17 have ADHD, and symptoms often persist into adulthood. Treatment is usually decided by pediatricians, psychiatrists, and primary care prescribers, making this Zevra Therapeutics, Inc.'s most established customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with idiopathic hypersomnia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKP1077 targets patients with idiopathic hypersomnia, a rare CNS sleep disorder with only a few approved options, including Xywav. The segment is small but highly unmet, and it fits Zevra Therapeutics, Inc.'s rare-disease focus on narrow, high-need populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with narcolepsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with narcolepsy are a clear fit for Zevra Therapeutics, Inc., since KP1077 is also being studied for this rare sleep disorder. Narcolepsy affects about 1 in 2,000 people, and many patients live with severe daytime sleepiness and functional impairment, so demand for differentiated therapies remains high.\u003c\/p\u003e\n\u003cp\u003eThis is a logical extension of the same development program, with a shared focus on improving wakefulness and daily function.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients with stimulant use disorder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKP879 targets patients with stimulant use disorder, a large unmet need with no FDA-approved drug therapy and rising care demand. In the U.S., SAMHSA has estimated millions of people with past-year stimulant misuse, so this segment will likely be reached through addiction specialists and behavioral health providers, making it a high-impact future market for Zevra Therapeutics, Inc.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge unmet need\u003c\/li\u003e\n\u003cli\u003eNo approved drug therapy\u003c\/li\u003e\n\u003cli\u003eUses specialty care channels\u003c\/li\u003e\n\u003cli\u003eHigh future market impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrescribers, payers, and health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. sells into three decision layers: prescribers start therapy, payers decide coverage, and health systems steer where and how patients get treated. That mix matters because access and utilization can shape sales more than patient demand alone.\u003c\/p\u003e\n\u003cp\u003eFor Zevra Therapeutics, Inc., these are the core economic customers for all approved and future products, since a single therapy can still face prior auth, formulary review, and institutional rules before a patient gets it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescribers drive first use.\u003c\/li\u003e\n\u003cli\u003ePayers control access and reimbursement.\u003c\/li\u003e\n\u003cli\u003eHealth systems shape utilization pathways.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra Targets ADHD, Rare Diseases, and Access Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. serves three buyer layers: patients, prescribers, and payers. AZSTARYS reaches the large ADHD market, while KP1077 and KP879 target smaller, high-need rare or specialty groups where access often depends on prior auth and specialist care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey need\u003c\/th\u003e\n\u003cth\u003eAccess driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD\u003c\/td\u003e\n\u003ctd\u003e~7.1M U.S. children\u003c\/td\u003e\n\u003ctd\u003ePrescribers, payers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIH\/narcolepsy\u003c\/td\u003e\n\u003ctd\u003eRare, unmet\u003c\/td\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStimulant use disorder\u003c\/td\u003e\n\u003ctd\u003eNo FDA drug\u003c\/td\u003e\n\u003ctd\u003eBehavioral care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and development spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. treats research and development as a core cost driver, with spending tied to preclinical work, Phase II trials, data analysis, formulation, and translational research. In FY2025, this outlay remained central to pipeline advancement, since every program needs funding before it can move toward later-stage clinical testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CMC costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and CMC costs cover drug substance and drug product runs, GMP testing, and stability work; for controlled-substance and specialty products, compliance and quality control add extra spend. These are recurring costs that support both commercial supply and clinical material, so they rise with batch volume and launch activity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, general, and administrative expense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSelling, general, and administrative expense is the cost base that funds Zevra Therapeutics, Inc.’s sales team, marketing, finance, legal, HR, and leadership support. These costs usually climb when Zevra expands commercialization and product launches, because revenue growth needs more field force, promotion, and corporate control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and compliance expense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. carries steady regulatory and compliance costs because every filing, safety review, and audit check must stay ready for FDA and global rules. These costs include pharmacovigilance and quality systems, and in 2025 they remained a fixed part of running a specialty pharma business, often scaling with each new product, label change, and inspection cycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiling prep never stops\u003c\/li\u003e\n\u003cli\u003eSafety monitoring is ongoing\u003c\/li\u003e\n\u003cli\u003eQuality systems protect launches\u003c\/li\u003e\n\u003cli\u003eCompliance reduces product risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicense fees and collaboration obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. relies on external licensing and collaboration deals, so cost structure can include milestone payments, royalties, and shared development spend. In biotech, royalty rates often run in the high single digits to low teens, and these variable costs must be weighed against each program’s revenue potential and probability of approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones raise cash needs\u003c\/li\u003e\n\u003cli\u003eRoyalties cut gross margin\u003c\/li\u003e\n\u003cli\u003eShared R\u0026amp;D lowers upfront burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s FY2025 Costs: R\u0026amp;D, SG\u0026amp;A, and Compliance Lead the Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc.’s FY2025 cost base is dominated by R\u0026amp;D, CMC\/manufacturing, SG\u0026amp;A, and FDA\/compliance work, with added variable costs from milestones and royalties on partnered programs. The mix is typical for a specialty pharma company: high fixed burn to advance pipelines, then higher operating spend as launches and safety monitoring scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost area\u003c\/th\u003e\n\u003cth\u003eFY2025 role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003ePipeline advancement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eCommercial and corporate build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003eFDA and safety oversight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAZSTARYS product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAZSTARYS is Zevra Therapeutics, Inc.'s FDA-approved ADHD product and a core cash-generating asset. In 2024, Zevra reported AZSTARYS net product revenue of about $37 million, and this stream still depends on payer access, prescriber uptake, and patient persistence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPADAZ product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPADAZ adds a marketed pain product to Zevra Therapeutics, Inc.’s 2025 revenue mix, giving the company a second commercial stream beyond its other therapies. Its sales depend on prescribing, payer access, and supply execution, so even modest APADAZ uptake helps diversify product revenue and reduce concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture sales from KP1077\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf approved, KP1077 could add a new revenue line in idiopathic hypersomnia and narcolepsy, two underserved sleep-disorder markets; narcolepsy affects about 1 in 2,000 people in the U.S. The asset is still clinical-stage, so Zevra Therapeutics, Inc. has meaningful upside here if development succeeds and access is secured.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture sales from KP879\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKP879 could become a long-term revenue stream for Zevra Therapeutics, Inc. if it wins approval in stimulant use disorder, a field with no FDA-approved medicines and millions of affected patients in the U.S. alone. Commercial sales would still hinge on regulatory success and payer access, so near-term value is optionality, not booked revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved revenue today\u003c\/li\u003e\n\u003cli\u003eHigh unmet need, large patient pool\u003c\/li\u003e\n\u003cli\u003eSales depend on FDA and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing, milestone, and royalty income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. can earn non-product cash from licensing deals through upfront fees, development milestones, and sales royalties. For a specialty biotech, even one partner deal can fund R\u0026amp;D and lower dilution pressure; in its model, this stream matters because external partners can turn pipeline progress into cash before product sales scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront cash starts the deal.\u003c\/li\u003e\n\u003cli\u003eMilestones pay on progress.\u003c\/li\u003e\n\u003cli\u003eRoyalties pay on sales.\u003c\/li\u003e\n\u003cli\u003eHelps fund R\u0026amp;D and cut dilution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra Revenue Centers on AZSTARYS, with Pipeline Upside Ahead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. revenue is still concentrated in product sales, led by AZSTARYS, which generated about $37 million in 2024 net product revenue. APADAZ adds a second commercial line, while KP1077 and KP879 remain pipeline optionality; licensing fees, milestones, and royalties can add non-product cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024-2025 status\u003c\/th\u003e\n\u003cth\u003eRevenue type\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAZSTARYS\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPADAZ\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKP1077\u003c\/td\u003e\n\u003ctd\u003eClinical stage\u003c\/td\u003e\n\u003ctd\u003eFuture sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKP879\u003c\/td\u003e\n\u003ctd\u003eClinical stage\u003c\/td\u003e\n\u003ctd\u003eFuture sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003ctd\u003eUpfront, milestones, royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235185631497,"sku":"zvra-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/zvra-business-model.webp?v=1785737019","url":"https:\/\/dcfanalyst.com\/products\/zvra-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}